Compare Divis Laboratories with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PFIZER - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PFIZER DIVIS LABORATORIES/
PFIZER
 
P/E (TTM) x 57.8 43.2 133.7% View Chart
P/BV x 13.3 7.1 186.3% View Chart
Dividend Yield % 0.5 0.5 96.0%  

Financials

 DIVIS LABORATORIES   PFIZER
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
PFIZER
Mar-19
DIVIS LABORATORIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,6393,840 42.7%   
Low Rs1,1152,080 53.6%   
Sales per share (Unadj.) Rs186.3455.0 41.0%  
Earnings per share (Unadj.) Rs51.093.8 54.3%  
Cash flow per share (Unadj.) Rs57.3109.4 52.4%  
Dividends per share (Unadj.) Rs16.0022.50 71.1%  
Dividend yield (eoy) %1.20.8 152.8%  
Book value per share (Unadj.) Rs261.8658.2 39.8%  
Shares outstanding (eoy) m265.4745.75 580.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.46.5 113.6%   
Avg P/E ratio x27.031.6 85.6%  
P/CF ratio (eoy) x24.027.1 88.8%  
Price / Book Value ratio x5.34.5 117.0%  
Dividend payout %31.424.0 130.9%   
Avg Mkt Cap Rs m365,592135,420 270.0%   
No. of employees `00011.82.6 450.3%   
Total wages/salary Rs m5,4233,238 167.4%   
Avg. sales/employee Rs Th4,175.17,911.4 52.8%   
Avg. wages/employee Rs Th457.71,230.9 37.2%   
Avg. net profit/employee Rs Th1,141.81,630.7 70.0%   
INCOME DATA
Net Sales Rs m49,46320,815 237.6%  
Other income Rs m1,5561,674 93.0%   
Total revenues Rs m51,01922,489 226.9%   
Gross profit Rs m18,7185,712 327.7%  
Depreciation Rs m1,689714 236.6%   
Interest Rs m3573 48.0%   
Profit before tax Rs m18,5516,599 281.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0232,309 217.6%   
Profit after tax Rs m13,5274,291 315.3%  
Gross profit margin %37.827.4 137.9%  
Effective tax rate %27.135.0 77.4%   
Net profit margin %27.320.6 132.7%  
BALANCE SHEET DATA
Current assets Rs m46,50127,167 171.2%   
Current liabilities Rs m8,4688,917 95.0%   
Net working cap to sales %76.987.7 87.7%  
Current ratio x5.53.0 180.3%  
Inventory Days Days13168 192.9%  
Debtors Days Days8630 285.2%  
Net fixed assets Rs m25,7978,862 291.1%   
Share capital Rs m531458 116.0%   
"Free" reserves Rs m68,96229,656 232.5%   
Net worth Rs m69,49330,113 230.8%   
Long term debt Rs m025 0.0%   
Total assets Rs m80,38339,400 204.0%  
Interest coverage x531.091.5 580.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 116.5%   
Return on assets %16.911.1 152.4%  
Return on equity %19.514.2 136.6%  
Return on capital %26.722.1 120.8%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,238428 9,628.2%   
Fx outflow Rs m12,405786 1,577.5%   
Net fx Rs m28,833-358 -8,051.5%   
CASH FLOW
From Operations Rs m9,543978 975.7%  
From Investments Rs m-6,854351 -1,951.6%  
From Financial Activity Rs m-2,459-1,099 223.9%  
Net Cashflow Rs m230231 99.5%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 11.8 7.5 157.3%  
FIIs % 19.0 4.9 387.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 23.7 72.6%  
Shareholders   31,796 85,207 37.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 500 Points Lower; Dow Futures Down by 77 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.

Related Views on News

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 27, 2021 03:16 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS